Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ENROLLING_BY_INVITATION
9999 participants
OBSERVATIONAL
2007-03-31
2050-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Brain Tissue Specimen Collection
NCT00593203
Assess Fibrin in Brains With AD/ADRD
NCT05336695
Identification of Biomarkers Sensitive to Disease Progression in Patients With Mild Cognitive Impairment
NCT01425957
Blood Vessel Anatomy and Blood Flow Regulation
NCT05396287
Brain Blood Flow: Age and Gender
NCT02840851
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The WBDP provides approved researchers access to indefinitely-stored postmortem brain tissues and post-mortem biospecimens (subject to the availability of remaining stock). Postmortem biospecimens also include CSF and whole blood.
The WBDP staff promotes and educates the lay community on the importance of brain donation.
Goal/Objectives The overall goal of the WBDP is to function as a useful brain tissue and biospecimen repository by distributing these materials to approved researchers studying neurodegenerative diseases, particularly Alzheimer's disease (AD).
To achieve this goal, the WBDP has adopted the following overall objectives:
1. To serve as the tissue and biospecimen repository for the Wisconsin ADRC and Wisconsin ADRC-affiliated studies. In this role, the WBDP will support collaborative research by providing postmortem tissues, biospecimens, and genetic/genomic data for AD and other neurodegenerative illnesses to approved researchers, whether at the University of Wisconsin-Madison or other approved institutions. The investigators will also promote data and sample sharing with ADRC Clinical Core, WRAP, and ADRC-affiliated studies such as ADNI, DOD-ADNI, and ADNI Brain Bank.
2. To establish a registered group of individuals who intend to donate their brain tissue and biospecimens after death for neurodegenerative-disease related research (the WBDP Registry).
3. To oversee all aspects of brain tissue and biospecimen collection and management (their procurement, indefinite storage, and distribution to approved researchers).
4. To collaborate with the National Alzheimer's Coordinating Center (NACC), the National Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD) and similar organizations, by providing coded biologic samples and data, inclusive of genetic data, in order to further AD research.
Due to the nature of this study, no specific number of subjects is being proposed. This will be an ongoing brain donation registry until funding is not renewed.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
OTHER
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Falls into one of the following categories:
* Current or previous study participants involved in the ADRC Clinical Core, WRAP study, or other select ADRC-affiliated studies, or donors of special circumstance, including healthy controls, if approved on a case-by-case basis by the WBDP PI. Please note, ADRC-affiliated studies are not inclusive of ADRC-affiliated industry-sponsored studies.
* Is a parent of either an ADRC Clinical Core or WRAP study participant, or is a spouse of a WRAP study participant.
Exclusion Criteria
* Subjects with a medical condition/disease that would exclude them from the spectrum of utility/interest to researchers as determined by a WBDP Neuropathologist:
1. Persons with Hepatitis B or C
2. Severe Traumatic Brain Injury
3. Positive CJD diagnosis
4. Persons with HIV/AIDS
5. Persons with brain tumors or blood clots that affect neurologic status, therefore creating a problem between diagnosing AD status and healthy status
6. Cancer that has metastasized to the brain
7. Radiation treatment to the head
8. Other infectious diseases that would be hazardous to staff handling the tissue
9. Prolonged ventilator dependency prior to death as determined by the Neuropathologist
* Subjects who lack capacity to provide informed consent with no activated Power of Attorney (POA) for Healthcare, activated POA for Research, or legal guardianship (if not near death), or (if at or near death) have no spouse, parent, relative or friend willing/able to complete consent and other donation paperwork.
* Subjects who otherwise have incomplete history or incomplete donation paperwork before a recovery can begin.
* Subjects younger than 18 years of age.
* An expected post-mortem interval (PMI) of greater than 16 hours for non-ADRC or non-WRAP participants. PMI is the time between death and the anticipated time of brain removal at autopsy. Families and recovery agencies are made aware of this time constraint when consenting for the recovery process. If a patient becomes ineligible due to PMI, the family and funeral home will be notified immediately. Diversions from this exclusion can be made by a WBDP PI or Co-PI.
* Medical conditions that would put researchers at risk.
* Other contingencies, as determined by the PI, that make enrollment impractical or unsafe.
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Washington
OTHER
National Institute on Aging (NIA)
NIH
University of Wisconsin, Madison
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Shahriar Salamat, MD PHD
Role: PRINCIPAL_INVESTIGATOR
University of Wisconsin, Madison
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Wisconsin Madison
Madison, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
H-2010-0037
Identifier Type: OTHER
Identifier Source: secondary_id
2014-1484
Identifier Type: OTHER
Identifier Source: secondary_id
A534255
Identifier Type: OTHER
Identifier Source: secondary_id
GERIATRICS AND ADULT
Identifier Type: OTHER
Identifier Source: secondary_id
H-2010-0037
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.